Shotlee LogoShotlee
Blog
Download on theApp Store
Become aBeta Tester
Skip to main content
Ozempic Arrives in India, Weight Loss Medication Priced Under $25 Weekly - Featured image
Health

Ozempic Arrives in India, Weight Loss Medication Priced Under $25 Weekly

The weight loss drug Ozempic has been introduced in India by Novo Nordisk, with a weekly cost of $24.35 for 0.25mg doses. This move occurs amidst increasing global demand for weight management solutions. India represents a significant market due to its high rates of type 2 diabetes and obesity.

Shotlee·December 12, 2025·Updated Jan 27, 2026·2 min read
Share:

Contents

  1. 01Ozempic Launches in India
  2. 02Pricing Details
  3. 03Ozempic's Popularity and Benefits
  4. 04Market Context

Ozempic Launches in India

The weight loss medication Ozempic was released in India on Friday. The 0.25mg doses are priced at $24.35 per week.

Pharmaceutical company Novo Nordisk initiated this action as demand for weight loss therapies increases globally. The company stated that Ozempic will be available in injectable pens, with dosages of 0.25mg, 0.5mg, and 1mg. Health tracking apps like Shotlee can help monitor progress for individuals using such medications.

Pricing Details

Monthly costs in India have been established at 8,800 rupees ($97) for a 0.25mg dose. The 0.5mg dose will cost 10,170 rupees, while the 1mg dose is priced at 11,175 rupees per month. Each pen provides four weekly doses.

Ozempic's Popularity and Benefits

Ozempic, which gained approval from the US Food and Drug Administration in 2017 for treating Type 2 diabetes, has become increasingly popular. Its widespread use for weight loss is attributed to its appetite-suppressing qualities. Novo also noted its beneficial effects for individuals with cardiovascular and kidney problems.

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Become aBeta Tester

According to Vikrant Shrotriya, corporate vice president and managing director of Novo Nordisk India, "Ozempic also supports weight loss of up to 8kg in diabetic patients... therefore, this drug offers advantages beyond just controlling blood sugar levels."

Market Context

India has the second-largest population of individuals with Type 2 diabetes, following China. It also experiences rising obesity rates. This makes the country a crucial area for pharmaceutical firms competing for a portion of the rapidly expanding weight loss treatment market. Analysts project the sector will reach a valuation of $150 billion annually by the decade's end.

Novo launched Ozempic in India this month to establish a market presence before local companies introduce cheaper alternatives. Patents for semaglutide, the medication sold under the Ozempic and Wegovy brands, are set to expire in March 2026.

Original source: The National

View original article →
#Ozempic#weight loss#India#Novo Nordisk#diabetes#semaglutide
  1. Home
  2. Blog
  3. Ozempic Arrives in India, Weight Loss Medication Priced Under $25 Weekly

Related Articles

Sciwind Biosciences $495M Pfizer China Deal for Ecnoglutide GLP-1
GLP-1 Medications

Sciwind Biosciences $495M Pfizer China Deal for Ecnoglutide GLP-1

Sciwind Biosciences has secured a landmark $495 million commercialization deal with Pfizer China for Ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist. Approved for type 2 diabetes in China, it shows 15.1% placebo-adjusted weight loss in trials. This partnership aims to address rising obesity rates amid national health initiatives.

NHS Pays GPs Incentives for Mounjaro, Wegovy Prescriptions
GLP-1 Medications

NHS Pays GPs Incentives for Mounjaro, Wegovy Prescriptions

The UK Government has announced financial incentives for GPs to boost prescriptions of weight-loss injections Mounjaro and Wegovy on the NHS. Eight months into the mass rollout, not all practices are participating, prompting £25 million in funding for fairer access. Health Secretary Wes Streeting calls it a 'game changer' for obesity, but experts warn of workload risks.

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Get Started

Resources

  • Health Blog
  • Support Center
  • System Status

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with ♥ for the community